Biointron Biological USA Inc. has made significant strides in the field of antibody discovery by introducing RushData, an innovative workflow that seamlessly integrates gene synthesis, rapid CHO expression, and high-throughput antibody assays. This advancement promises to enhance the efficiency of AI-driven antibody discovery programs by providing structured experimental datasets that accelerate the transition from computational design to validated experimental data.
Streamlining the Workflow
The process of converting AI-generated antibody sequences into validated experimental data often encounters delays due to the complexity of coordinating multiple steps: gene synthesis, antibody expression, purification, binding assays, and data processing. These bottlenecks can hinder the pace of discovery, especially when rapid iterations of design are required. Biointron’s RushData workflow addresses these challenges by consolidating these steps into a single, efficient pipeline.
The Heart of RushData
At the core of RushData is Biointron’s 1-day transient CHO expression system, which allows for the swift conversion of synthesized antibody sequences into assay-ready materials. This expedited approach enables researchers to assess antibodies directly at the supernatant level during early-stage screening. By reducing the reliance on purification before obtaining initial expression and binding data, this workflow aligns experimental timelines with the rapid cycles inherent in AI design processes.
Three Levels of Service
RushData offers three distinct service levels, catering to varying depths of experimental characterization:
- Basic: This level focuses on rapid screening at the supernatant level, providing essential metrics such as expression titers and binding measurements. It allows for the early evaluation of large panels of candidate antibodies.
- Standard: This tier incorporates antibody purification and advanced affinity characterization techniques, including bio-layer interferometry (BLI) and surface plasmon resonance (SPR). These methods facilitate a deeper understanding of antibody interactions.
-
Premium: The most comprehensive service level, Premium, adds early developability assessments. It employs advanced techniques such as differential scanning fluorimetry for thermal stability, affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) for self-interaction analysis, and polyspecificity testing to evaluate polyreactivity.
Together, these services provide multidimensional profiles of candidate antibodies, enabling researchers to select those with optimal combinations of expression, binding, affinity, and developability characteristics rather than relying solely on binding performance.
Integration with AI Platforms
RushData results are delivered as structured datasets, accessible via an API. This feature allows research teams to seamlessly incorporate wet-lab measurements into their internal dashboards, computational models, or automated antibody discovery pipelines, enhancing the overall efficiency and effectiveness of the research process.
Leveraging CHO Cells
Chinese Hamster Ovary (CHO) cells are the preferred choice for therapeutic antibody production due to their ability to facilitate proper protein folding and post-translational modifications. By utilizing CHO expression during the early stages of experimental validation, Biointron enables AI discovery teams to acquire data that is not only relevant but also reflective of mammalian expression systems used in later stages of antibody development.
A Legacy of Excellence
Since its founding in 2012, Biointron has established itself as a leader in the contract research organization (CRO) space, providing antibody production and characterization services to over 3,000 biotechnology and pharmaceutical companies across more than 20 countries. With offices in Cambridge, Massachusetts, and Piscataway, New Jersey, as well as facilities in China, Biointron continues to push the boundaries of antibody discovery. The 1-day CHO workflow enhances the company’s existing RushMab small-scale antibody expression packages, adapting its successful platform to meet the demands of high-throughput data generation necessary for AI-driven discovery.
Conclusion
Biointron’s RushData workflow represents a pivotal advancement in the realm of AI-driven antibody discovery. By streamlining the gene-to-data process, the company not only accelerates the pace of scientific exploration but also enhances the quality of experimental outcomes. As the biotech landscape evolves, Biointron’s commitment to innovation positions it as a key player in the future of antibody development.
- Key Takeaways:
- RushData integrates multiple stages of antibody discovery into a single, efficient workflow.
- The 1-day transient CHO expression system accelerates the validation process.
- Three service levels cater to varying depths of experimental characterization.
- Structured datasets facilitate integration with AI-driven research platforms.
- Biointron’s history of excellence supports its role as a leader in the biotech industry.
Read more → finance.yahoo.com